{
"id":"mk19_a_gi_q047",
"number":47,
"bookId":"gi",
"correctAnswer":"A",
"title":"Question 47",
"stimulus":[
{
"type":"p",
"hlId":"ccd24c",
"children":[
"A 29-year-old woman is evaluated at routine follow-up for chronic hepatitis B virus infection. She is asymptomatic, has no other medical conditions, and does not take any medications. She is negative for hepatitis C virus and HIV infections."
]
},
{
"type":"p",
"hlId":"f78abf",
"children":[
"On physical examination, vital signs and other findings are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"62ea29",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Aminotransferase, alanine (ALT)",
"children":[
"Alanine aminotransferase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"59929c",
"class":"cell text l",
"children":[
"89 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a3a396",
"class":"cell text l",
"children":[
"Hepatitis B core antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"aa7caf",
"class":"cell text l",
"children":[
"Hepatitis B e antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"20cc3d",
"class":"cell text l",
"children":[
"Hepatitis B e antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"7e4439",
"class":"cell text l",
"children":[
"Hepatitis B virus DNA"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"caae99",
"class":"cell text l",
"children":[
"80,000 U/mL"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"f0c10b",
"children":[
"Liver ultrasound is normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Antiviral therapy"
}
},
{
"letter":"B",
"text":{
"__html":"Clinical observation and surveillance"
}
},
{
"letter":"C",
"text":{
"__html":"Hepatitis B virus immune globulin"
}
},
{
"letter":"D",
"text":{
"__html":"Liver biopsy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4dcd2c",
"children":[
"Treatment of hepatitis B virus (HBV) infection is advised for patients with acute liver failure, chronic infection in the immune-active phase or reactivation phase, or cirrhosis and for selected immunosuppressed patients."
]
},
{
"type":"keypoint",
"hlId":"eb29c4",
"children":[
"Immune-active chronic HBV infection is defined by presence of hepatitis B core antibody, elevated alanine aminotransferase level, and HBV viral load greater than 2000 U/mL in patients negative for hepatitis B e antigen and greater than 20,000 U/mL in patients positive for hepatitis B e antigen."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a99572",
"children":[
"The most appropriate management is antiviral therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Treatment for hepatitis B virus (HBV) infection is advised for patients with acute liver failure, chronic infection in the immune-active phase or reactivation phase, or cirrhosis and for selected immunosuppressed patients. Chronic HBV infection is diagnosed after 6 months in patients with persistent hepatitis B surface antigen detected in serum. Chronic HBV infection is divided into phases of disease. Patients in the immune-active phase or reactivation phase have an elevated alanine aminotransferase (ALT) level, presence of hepatitis B core antibody, and an elevated HBV DNA level (>20,000 U/mL in hepatitis B e antigen [HBeAg]–positive disease or >2000 U/mL in HBeAg-negative disease; a rise above baseline HBV DNA level in the reactivation phase). This patient has chronic HBV infection in the immune-active, HBeAg-positive phase. First-line antiviral treatment is entecavir or tenofovir for most patients. Pegylated interferon can also be used."
]
},
{
"type":"p",
"hlId":"2707b4",
"children":[
"Treatment is necessary to decrease hepatic inflammation, the risk for progression to fibrosis, and the eventual cirrhosis that will occur without treatment. Clinical observation and surveillance (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not the best option for a patient with chronic HBV infection in the immune-active phase."
]
},
{
"type":"p",
"hlId":"da91ef",
"children":[
"Patients with chronic HBV infection should receive appropriate immunizations, particularly hepatitis A virus vaccination. HBV immune globulin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is indicated for postexposure prophylaxis following acute exposure to HBV. It is also recommended for prevention of HBV recurrence after liver transplantation in HBsAg-positive transplant recipients. Hepatitis B immune globulin is not indicated for treatment of active HBV infection and is ineffective in the treatment of chronic active HBV infection."
]
},
{
"type":"p",
"hlId":"036c59",
"children":[
"A liver biopsy–confirmed diagnosis of cirrhosis can be helpful in determining the need for antiviral treatment in patients with chronic HBV infection. However, this patient with immune-active infection already has an indication for treatment. Furthermore, cirrhosis is unlikely in an asymptomatic patient without evident complications from cirrhosis and a normal hepatic ultrasound. Therefore, a liver biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not needed."
]
}
],
"relatedSection":"mk19_a_gi_s6_2_2",
"objective":{
"__html":"Treat hepatitis B virus infection in the immune-active phase."
},
"references":[
[
"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29405329",
"target":"_blank"
},
"children":[
"PMID: 29405329"
]
},
" doi:10.1002/hep.29800"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":73,
"B":18,
"C":4,
"D":6,
"E":0
},
"hlIds":[
"ccd24c",
"f78abf",
"a462a3",
"62ea29",
"59929c",
"a3a396",
"328929",
"aa7caf",
"ffb935",
"20cc3d",
"328929",
"7e4439",
"caae99",
"f0c10b",
"cb2b54",
"4dcd2c",
"eb29c4",
"a99572",
"2707b4",
"da91ef",
"036c59"
]
}